MiNK Therapeutics, Inc. (INKT)
NASDAQ: INKT · Real-Time Price · USD
11.05
-0.14 (-1.25%)
At close: Feb 11, 2026, 4:00 PM EST
11.34
+0.29 (2.65%)
After-hours: Feb 11, 2026, 6:32 PM EST
MiNK Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
23
Market Cap
51.87M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| TScan Therapeutics | 8.42M |
| Radiopharm Theranostics | 8.20M |
| Lipocine | 4.32M |
| Nutriband | 2.28M |
| InflaRx | 73.73K |
INKT News
- 7 days ago - MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia - GlobeNewsWire
- 4 weeks ago - MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease - GlobeNewsWire
- 2 months ago - MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors - GlobeNewsWire
- 3 months ago - MiNK Therapeutics, Inc. (INKT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025 - GlobeNewsWire
- 4 months ago - MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors - GlobeNewsWire
- 4 months ago - MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA - GlobeNewsWire
- 5 months ago - MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development - GlobeNewsWire